Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma (ENDOVIE)

A

ARCAGY/ GINECO GROUP

Status

Completed

Conditions

Metastatic Cancer
Recurrent Cancer
Advanced Cancer
Endometrial Cancer
Oncology

Treatments

Drug: Chemotherapy

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05364905
GINECO-EN106

Details and patient eligibility

About

This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.

Enrollment

200 patients

Sex

Female

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult women ≥ 18 years at index date.
  • Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible.
  • Index date should represent at least the first* or second line** chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019.
  • do not express refusal to her personal data processing or did not express her refusal for deceased patients.

Exclusion criteria

  • No clinical records for tumor imaging or administration of anti-cancer therapy.
  • Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion.
  • Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased).
  • Patient did not receive chemotherapy systemic treatment.
  • Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.

Trial design

200 participants in 2 patient groups

Cohort 1
Description:
Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
Treatment:
Drug: Chemotherapy
Cohort 2
Description:
Patients in second line treatment (after one prior systemic chemotherapy) in 2019
Treatment:
Drug: Chemotherapy

Trial contacts and locations

30

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems